Indian medicinal plants are effective in the treatment and management of COVID-19

Chandra, Subhash; Palai, Santwana; FERREIRA-MATIAS, EDINARDO FAGNER; PITA-NETO, IVO CAVALCANTE; GOMES-RAMALHO, C鞢ERO LUCAS; ANDRADE, EDLANE MARTINS DE; ALMEIDA, RAY SILVA DE; IRITI, MARCELLO; MELO-COUTINHO, HENRIQUE DOUGLAS

doi:10.32604/biocell.2023.026081

Cited by 3 publications

(1 citation statement)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic targeting plans for any of the three principal druggable proteins of SARS-CoV-2 usually begin with computational assessments (Rabie, 2021). Natural products/ ingredients occupy a large part of these speculative preparatory studies (Rabie, 2022b;Chandra et al, 2023;Zrieq et al, 2021); however, not all of them reached the final pharmacological and clinical confirmations.…”

Section: Major Targeted Sars-cov-2 Proteinsmentioning

confidence: 99%

Future of the current anticoronaviral agents: A viewpoint on the validation for the next COVIDs and pandemics

RABIE

2023

BIOCELL

View full text Add to dashboard Cite

Despite the global decline in the severity of the coronavirus disease 2019 (COVID-19) cases, the disease still represents a major concern to the relevant scientific and medical communities. The primary concern of drug scientists, virologists, and other concerned specialists in this respect is to find ready-to-use suitable and potent anticoronaviral therapies that are broadly effective against the different species/strains of the coronaviruses in general, not only against the current and previous coronaviruses (e.g., the recently-appeared severe acute respiratory syndrome coronavirus 2 "SARS-CoV-2"), i.e., effective antiviral agents for treatment and/or prophylaxis of any coronaviral infections, including those of the coming ones from the next species and strains (if any). As an expert in this field, I tried, in this up-to-date perspective "viewpoint" article, to evaluate the suitability and applicability of using the currently-available anticoronaviral agents for the next coronavirus diseases (COVIDs) and coronaviral pandemics, highlighting the most important general guidelines that should be considered in the next pandemics from the therapeutic points of view.

show abstract

Section: Major Targeted Sars-cov-2 Proteinsmentioning

confidence: 99%

Future of the current anticoronaviral agents: A viewpoint on the validation for the next COVIDs and pandemics

RABIE

2023

BIOCELL

View full text Add to dashboard Cite

show abstract

Predictive Assessment of the Antiviral Properties of Imperata cylindrica against SARS‐CoV‐2

Tatsing Foka,

Tumelo Mufhandu

2024

Advances in Virology

View full text Add to dashboard Cite

The omicron variant and its sublineages are highly contagious, and they still constitute a global source of concern despite vaccinations. Hospitalizations and mortality rates resulting from infections by these variants of concern are still common. The existing therapeutic alternatives have presented various setbacks such as low potency, poor pharmacokinetic profiles, and drug resistance. The need for alternative therapeutic options cannot be overemphasized. Plants and their phytochemicals present interesting characteristics that make them suitable candidates for the development of antiviral therapeutic agents. This study aimed to investigate the antiviral potential of Imperata cylindrica (I. cylindrica). Specifically, the objective of this study was to identify I. cylindrica phytochemicals that display inhibitory effects against SARS‐CoV‐2 main protease (Mpro), a highly conserved protein among coronaviruses. Molecular docking and in silico pharmacokinetic assays were used to assess 72 phytocompounds that are found in I. cylindrica as ligands and Mpro (6LU7) as the target. Only eight phytochemicals (bifendate, cylindrene, tabanone, siderin, 5‐hydroxy‐2‐[2‐(2‐hydroxyphenyl)ethyl]‐4H‐1‐benzopyran‐4‐one, maritimin, 5‐methoxyflavone, and flavone) displayed high binding affinities with Mpro with docking scores ranging from −5.6 kcal/mol to −9.1 kcal/mol. The in silico pharmacokinetic and toxicological assays revealed that tabanone was the best and safest phytochemical for the development of an inhibitory agent against coronavirus main protease. Thus, the study served as a baseline for further in vitro and in vivo assessment of this phytochemical against Mpro of SARS‐CoV‐2 variants of concern to validate these in silico findings.

show abstract

Repurposing of Plant-based Antiviral Molecules for the Treatment of COVID-19

Khazir,

Ahmed,

Thakur

et al. 2024

CTMC

View full text Add to dashboard Cite

COVID-19, stemming from SARS-CoV-2, poses a formidable threat to global healthcare, with a staggering 77 million confirmed cases and 690,067 deaths recorded till Decem-ber 24, 2023. Given the absence of specific drugs for this viral infection, the exploration of novel antiviral compounds becomes imperative. High-throughput technologies are actively engaged in drug discovery, and there is a parallel effort to repurpose plant-based molecules with established antiviral properties. In this context, the review meticulously delves into the potential of plant-based folk remedies and existing molecules. These substances have showcased substantial viral inhibition in diverse in vivo, in silico, and in vitro studies, particularly against critical viral protein targets, including SARS-CoV-2. The findings position these plant-based molecules as promising antiviral drug candidates for the swift advancement of treatments for COVID-19. It is noteworthy that the inherent attributes of these plant-based molecules, such as their natural origin, potency, safety, and cost-effectiveness, contribute to their appeal as lead candidates. The review advocates for further exploration through comprehensive in vivo studies conducted on animal models, em-phasizing the potential of plant-based compounds to help in the ongoing quest to develop effec-tive antivirals against COVID-19.

show abstract

Indian medicinal plants are effective in the treatment and management of COVID-19

Cited by 3 publications

References 120 publications

Future of the current anticoronaviral agents: A viewpoint on the validation for the next COVIDs and pandemics

Future of the current anticoronaviral agents: A viewpoint on the validation for the next COVIDs and pandemics

Predictive Assessment of the Antiviral Properties of Imperata cylindrica against SARS‐CoV‐2

Repurposing of Plant-based Antiviral Molecules for the Treatment of COVID-19

Contact Info

Product

Resources

About